Ketamine for Depression
A medically responsible look at how ketamine fits into depression care today — mechanisms, protocols, durability, comparative effectiveness, and the limits of the evidence.
Condition overview
Major depressive disorder (MDD) is a common, often chronic mood condition involving persistent low mood, loss of interest, and changes in sleep, appetite, energy, and cognition. Treatment-resistant depression (TRD) generally describes MDD that has not responded adequately to two or more standard antidepressant trials of adequate dose and duration.
Depression is heterogeneous. Two people with the same diagnosis can have very different symptom profiles, biological drivers, and treatment histories — which is part of why no single intervention works for everyone.
Current standard treatments
- Evidence-based psychotherapy (such as CBT, IPT, or behavioral activation)
- SSRI and SNRI antidepressants as first-line medication
- Augmentation strategies (atypical antipsychotics, lithium, thyroid hormone)
- Neuromodulation (TMS or ECT) for severe or resistant cases
- Lifestyle, sleep, exercise, and social support as foundational care
How ketamine differs mechanistically
Most traditional antidepressants act primarily on monoamine systems (serotonin, norepinephrine, dopamine) and take weeks to show benefit. Ketamine acts on the glutamate system — primarily as an NMDA receptor antagonist — and is thought to trigger downstream changes in synaptic plasticity that can shift depressive symptoms rapidly. See how ketamine works for the neuroscience in detail.
Where ketamine may help
For adults with treatment-resistant depression, ketamine and esketamine offer a different mechanism of action and a much faster timeline than traditional antidepressants. This can matter most for people with severe symptoms, acute suicidality, or a long history of failed trials — under appropriate medical supervision and within a broader plan.
What the research supports
- Rapid symptom reductions in TRD across multiple randomized trials
- FDA approval of esketamine following pivotal trials in TRD and in MDD with acute suicidal ideation
- Evidence that repeated dosing supports more durable response than a single infusion
- Short-term reductions in suicidal ideation in several controlled trials
- Mixed evidence on long-term outcomes, optimal maintenance schedules, and broader populations
Typical protocols
Protocols vary. IV racemic ketamine for depression is commonly given as a 0.5 mg/kg infusion over roughly 40 minutes, often six sessions across two to three weeks, then tapered maintenance. Intranasal esketamine follows a structured twice-weekly induction phase defined by its label, then weekly or biweekly maintenance. Real protocols depend on response, tolerability, and clinician judgment.
Durability and maintenance
Without maintenance, benefit from a single infusion often fades in days to a couple of weeks. With a structured induction and maintenance plan, many responders sustain meaningful improvement for months — though relapse is common, and ongoing therapy, medication, and lifestyle support typically remain important.
Risks and limitations
Ketamine is not benign. Transient dissociation, elevated blood pressure, nausea, and emotional intensity are common during sessions. Cardiovascular strain, urinary toxicity with high-dose recreational use, and psychological dependence are documented risks. Long-term safety data for sustained therapeutic use is still developing. See safety & eligibility for details.
Who is not a candidate
- Uncontrolled cardiovascular disease or unstable blood pressure
- Active psychosis or untreated bipolar mania
- Active substance use disorders, particularly involving dissociatives
- Pregnancy
- Certain medication interactions or medical contraindications a clinician identifies during screening
Related: how ketamine works, ketamine research, depression overview.
Frequently asked questions
Is ketamine FDA-approved for depression?+
Esketamine (Spravato), the nasal-spray form, is FDA-approved for treatment-resistant depression and for depressive symptoms in adults with major depressive disorder with acute suicidal ideation, within a restricted REMS program. Generic IV/IM racemic ketamine for depression is typically administered off-label.
How fast does it work?+
Some patients report reductions in depressive symptoms within hours to a few days after a single subanesthetic infusion. Many require a series of repeated doses for benefits to persist beyond one to two weeks.
Who is a candidate?+
Generally adults with major depressive disorder — most often treatment-resistant — after a thorough psychiatric and medical screening. It is not considered a first-line treatment and is not appropriate for everyone.
How long do effects last?+
Single-dose effects often fade within days to a couple of weeks. Durability typically requires repeated sessions, a maintenance plan, and integration with broader mental health care.
Is ketamine a cure for depression?+
No. It can produce rapid but often time-limited symptom reduction for some people. It is one component of a broader treatment plan, not a cure, and relapse is common without ongoing care.
What is a typical induction protocol?+
A common pattern is six subanesthetic infusions over two to three weeks, followed by tapered maintenance dosing based on response. Esketamine has its own twice-weekly induction schedule defined by its label.
How does ketamine compare to traditional antidepressants?+
Traditional antidepressants (SSRIs, SNRIs) act on monoamine systems and typically take four to eight weeks to show benefit. Ketamine works on the glutamate system and can act within hours, but its effects are often shorter-lived without repeated dosing.
How does it compare to ECT?+
Electroconvulsive therapy (ECT) remains one of the most effective treatments for severe and treatment-resistant depression. Some head-to-head trials suggest ketamine is non-inferior for certain patients, but ECT still has the strongest evidence for the most severe cases.
Can ketamine help with suicidal ideation?+
Several trials and the esketamine label support short-term reductions in suicidal ideation. It is not a replacement for crisis care, hospitalization when needed, or ongoing safety planning.
Is ketamine covered by insurance?+
Coverage varies. Esketamine (Spravato) is more often covered when prescribed within its FDA-approved indications. IV ketamine for depression is typically off-label and frequently out-of-pocket.
What are common side effects?+
Transient dissociation, mild euphoria or sedation, elevated blood pressure and heart rate, nausea, dizziness, blurred vision, and emotional intensity during and shortly after sessions.
Can I stop my antidepressant if ketamine works?+
Do not stop or change any psychiatric medication without your prescriber. Abrupt discontinuation of antidepressants can cause withdrawal symptoms and relapse.
Educational use only. The content on this page is provided for general educational purposes and does not constitute medical advice, diagnosis, or treatment. Ketamine and related therapies carry risks and are appropriate only under qualified medical supervision. Always consult a licensed healthcare professional about your individual situation. Information may change as research evolves.